[go: up one dir, main page]

FIC20200050I1 - indakateroliasetaatti tai indakateroliksinafoaatti, edullisesti indakateroliasetaatti yhdessä mometasonifuroaatin ja glykopyrroniumin kanssa - Google Patents

indakateroliasetaatti tai indakateroliksinafoaatti, edullisesti indakateroliasetaatti yhdessä mometasonifuroaatin ja glykopyrroniumin kanssa

Info

Publication number
FIC20200050I1
FIC20200050I1 FIC20200050C FIC20200050C FIC20200050I1 FI C20200050 I1 FIC20200050 I1 FI C20200050I1 FI C20200050 C FIC20200050 C FI C20200050C FI C20200050 C FIC20200050 C FI C20200050C FI C20200050 I1 FIC20200050 I1 FI C20200050I1
Authority
FI
Finland
Prior art keywords
indacaterol
acetate
glycopyrronium
combination
xinafoate
Prior art date
Application number
FIC20200050C
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613159A external-priority patent/GB0613159D0/en
Priority claimed from GB0613156A external-priority patent/GB0613156D0/en
Priority claimed from GB0613160A external-priority patent/GB0613160D0/en
Priority claimed from GB0613158A external-priority patent/GB0613158D0/en
Priority claimed from EP06117129A external-priority patent/EP1878722A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of FIC20200050I1 publication Critical patent/FIC20200050I1/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
FIC20200050C 2006-06-30 2020-12-16 indakateroliasetaatti tai indakateroliksinafoaatti, edullisesti indakateroliasetaatti yhdessä mometasonifuroaatin ja glykopyrroniumin kanssa FIC20200050I1 (fi)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0613159A GB0613159D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613156A GB0613156D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613160A GB0613160D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613158A GB0613158D0 (en) 2006-06-30 2006-06-30 Organic compounds
EP06117129A EP1878722A1 (en) 2006-07-13 2006-07-13 Quinolinone derivatives and their pharmaceutical compositions

Publications (1)

Publication Number Publication Date
FIC20200050I1 true FIC20200050I1 (fi) 2020-12-16

Family

ID=38610531

Family Applications (2)

Application Number Title Priority Date Filing Date
FIC20200047C FIC20200047I1 (fi) 2006-06-30 2020-11-27 Indakateroliasetaatti tai indakateroliksinafoaatti yhdessä mometasonifuroaatin kanssa, edullisesti indakateroliasetaatti yhdessä mometasonifuroaatin kanssa
FIC20200050C FIC20200050I1 (fi) 2006-06-30 2020-12-16 indakateroliasetaatti tai indakateroliksinafoaatti, edullisesti indakateroliasetaatti yhdessä mometasonifuroaatin ja glykopyrroniumin kanssa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FIC20200047C FIC20200047I1 (fi) 2006-06-30 2020-11-27 Indakateroliasetaatti tai indakateroliksinafoaatti yhdessä mometasonifuroaatin kanssa, edullisesti indakateroliasetaatti yhdessä mometasonifuroaatin kanssa

Country Status (28)

Country Link
US (2) US8198450B2 (fi)
EP (1) EP2044025B1 (fi)
JP (1) JP5253392B2 (fi)
KR (1) KR101402398B1 (fi)
CN (1) CN101479245B (fi)
AU (1) AU2007264946B2 (fi)
BR (1) BRPI0713951B8 (fi)
CA (1) CA2654801C (fi)
CY (3) CY1113733T1 (fi)
DK (1) DK2044025T3 (fi)
ES (1) ES2396987T3 (fi)
FI (2) FIC20200047I1 (fi)
FR (2) FR20C1054I1 (fi)
HR (1) HRP20121074T1 (fi)
HU (2) HUS2000043I1 (fi)
IL (1) IL195796A (fi)
LT (2) LTC2044025I2 (fi)
LU (2) LUC00185I2 (fi)
MA (1) MA30540B1 (fi)
MX (1) MX2008016542A (fi)
MY (1) MY150468A (fi)
NO (3) NO341709B1 (fi)
NZ (1) NZ573292A (fi)
PL (1) PL2044025T3 (fi)
PT (1) PT2044025E (fi)
SI (1) SI2044025T1 (fi)
WO (1) WO2008000839A1 (fi)
ZA (1) ZA200809948B (fi)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2266656A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
KR20120120453A (ko) 2007-09-05 2012-11-01 화이자 리미티드 Ｎ4-(2,2-다이플루오로-4ｈ-벤조〔1,4〕옥사진-3-온)-6-일〕-5-플루오로-ｎ2-〔3-(메틸아미노카보닐메틸렌옥시)페닐〕2,4-피리미딘다이아민의 지나포에이트 염
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
CA2898700C (en) 2013-03-14 2022-07-19 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
EP3347345B1 (en) 2015-09-29 2019-07-31 Inke, S.A. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one l-tartrate
CN110724095B (zh) * 2019-09-12 2023-06-09 上海方予健康医药科技有限公司 一种茚达特罗乙酸盐的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05202301A (ja) * 1991-08-29 1993-08-10 Yamamoto Chem Inc ２−アニリノ−３−メチル−６−（Ｎ−ｎ−ブチル−Ｎ−シクロヘキシルアミノ）フルオランの結晶変態、その製造方法及びこの結晶変態を含有する記録材料
EP0688871A3 (en) * 1994-06-24 1998-07-08 Quest International B.V. Preparation of phytosphingosine derivative
FR2777279B1 (fr) * 1998-04-08 2004-08-13 Hoechst Marion Roussel Inc Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0127430D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
US7417051B2 (en) * 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
PE20050211A1 (es) 2003-04-02 2005-04-27 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
CA2521271C (en) 2003-04-04 2011-01-04 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
EP1869049B1 (en) 2005-03-21 2009-03-04 Eli Lilly And Company Imidazopyridazine compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors

Also Published As

Publication number Publication date
BRPI0713951B1 (pt) 2019-08-13
IL195796A0 (en) 2009-09-01
HK1127597A1 (en) 2009-10-02
HRP20121074T1 (hr) 2013-01-31
SI2044025T1 (sl) 2013-01-31
NO341709B1 (no) 2018-01-02
BRPI0713951A2 (pt) 2012-12-04
LTPA2020538I1 (lt) 2021-01-11
NO20090312L (no) 2009-01-28
DK2044025T3 (da) 2013-01-14
CN101479245A (zh) 2009-07-08
NO2020041I1 (no) 2020-11-23
FR20C1054I1 (fr) 2020-12-25
CY2020041I2 (el) 2021-03-12
LTPA2020535I1 (lt) 2020-12-28
CY2020038I2 (el) 2021-03-12
LUC00188I2 (fi) 2024-07-01
EP2044025B1 (en) 2012-10-03
JP2009541455A (ja) 2009-11-26
EP2044025A1 (en) 2009-04-08
CY2020038I1 (el) 2021-03-12
CA2654801C (en) 2014-08-19
KR20090023651A (ko) 2009-03-05
US20120316142A1 (en) 2012-12-13
ZA200809948B (en) 2009-05-25
LTC2044025I2 (lt) 2022-10-10
BRPI0713951B8 (pt) 2021-05-25
JP5253392B2 (ja) 2013-07-31
KR101402398B1 (ko) 2014-06-03
CY1113733T1 (el) 2016-06-22
MA30540B1 (fr) 2009-06-01
PL2044025T3 (pl) 2013-02-28
HUS2000053I1 (hu) 2020-12-28
US20090325912A1 (en) 2009-12-31
NO2020044I1 (no) 2020-12-07
AU2007264946A1 (en) 2008-01-03
CY2020041I1 (el) 2021-03-12
FR20C1063I1 (fr) 2021-01-22
WO2008000839A1 (en) 2008-01-03
MY150468A (en) 2014-01-30
US8198450B2 (en) 2012-06-12
FIC20200047I1 (fi) 2020-11-27
HUS2000043I1 (hu) 2020-12-28
MX2008016542A (es) 2009-01-19
CN101479245B (zh) 2013-05-22
PT2044025E (pt) 2012-12-17
IL195796A (en) 2016-03-31
ES2396987T3 (es) 2013-03-01
NZ573292A (en) 2011-03-31
AU2007264946B2 (en) 2011-01-20
LUC00185I2 (fi) 2024-07-01
CA2654801A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
FIC20200050I1 (fi) indakateroliasetaatti tai indakateroliksinafoaatti, edullisesti indakateroliasetaatti yhdessä mometasonifuroaatin ja glykopyrroniumin kanssa
EP2153838A4 (en) ANTI-NOROVIRUS AGENT AND COMPOSITION THEREOF
IL219268A (en) Anti-b79cd antibody, immunosuppressant and pharmacological agent that includes and uses it
DK3090748T3 (da) Sammensætninger, der omfatter nukleotid- og oligonukleotid-prodrugs
DE602006014147D1 (de) Aroma- und duftstoffzusammensetzung
PT2144998T (pt) Métodos e composições para vírus vivos atenuados
PL2124638T3 (pl) Kompozycja zwiększająca wydolność i jej zastosowanie
BRPI0918141A2 (pt) conjunto de embalagem para marinada sob demanda e método para fornecer o mesmo
ZA200802078B (en) Thiazolinones and oxazolinones and their use as PTP1B inhibitors
BRPI0809573A8 (pt) composição, e, método
ZA200904061B (en) Fuel composition and its use
IL206808A (en) Indolyl-pyridone history, their pharmaceutical preparations and their uses
DE602007000304D1 (de) Schützende und regenerierende Zusammensetzung
BRPI0917728A2 (pt) composição, uso da composição, e, método de prevenção da formação de espuma em uma composição
DE602006015807D1 (de) Abgeschwächter dengue-serotyp-2-stamm
IL207372A0 (en) Phenylpyrrole derivatives, compositions comprising the same and uses thereof
EP2315600A4 (en) COMPOSITIONS AND METHODS RELATING TO SIRT1 FUNCTION
BRPI0912321A2 (pt) embalagem com barreira de gás e absorção de líquido para empacotamento de produtos alimentícios
PL2235013T3 (pl) Podstawione związki tetrahydroimidazopirydynowe i ich zastosowanie w farmaceutykach
SE0601155L (sv) Gas- och vätsketät skyddsdräkt
IL196866A (en) Erythropoietin compounds, pharmaceuticals containing them and their uses
BRPI0809684A2 (pt) Embalagem, e embalagem
DK1886686T3 (da) Farmaceutisk sammensætning indeholdende mometasonfuroat
FR2929112B1 (fr) Composition de teinture comprenant au moins un derive de cyclanone et au moins un alcoxysilane
IL208168A0 (en) Tetrahydroisoquinoline derivatives, compositions comprising the same and use thereof